Alaunos Therapeutics company info

What does Alaunos Therapeutics do?
Alaunos Therapeutics (NASDAQ:TCRT) operates in the field of biotherapeutics, focusing on developing innovative cancer treatments. Its projects revolve around utilizing T-cell receptor (TCR) therapies to target solid tumors, an approach that represents a next step in personalized cancer treatment. The objective of Alaunos is to harness the body's own immune system to fight cancer more effectively, aiming to bring groundbreaking TCR therapies from the laboratory to patients. By pushing the boundaries of cancer treatment, Alaunos is dedicated to improving patient outcomes and quality of life. The company's work is underpinned by a commitment to scientific excellence and collaboration with leading research institutions to accelerate the development of its therapies.
Alaunos Therapeutics company media
Company Snapshot

Is Alaunos Therapeutics a public or private company?

key
Ownership
Public

How many people does Alaunos Therapeutics employ?

people
Employees
34

What sector is Alaunos Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Alaunos Therapeutics?

location pin
Head Office
Houston, United States

What year was Alaunos Therapeutics founded?

founded flag
Year Founded
1998
What does Alaunos Therapeutics specialise in?
/Immunotherapy Biologics /Oncology Treatments /Checkpoint Inhibitors /Antibody Therapies /Protein Therapeutics /Research Partnerships

What are the products and/or services of Alaunos Therapeutics?

Overview of Alaunos Therapeutics offerings
TCR-T cell therapy platform, focusing on treatments for solid tumors with proprietary TCRs targeting shared cancer-specific mutations.
Partnerships for clinical trial expansion, including collaborations with major pharmaceutical companies to test and develop TCR therapies.
In-house pipeline of TCR candidates, employing a high-throughput screening process to identify and enhance TCRs targeting the most prevalent mutations in cancers.
Manufacturing capabilities for TCR-T cell therapies, ensuring scalable and efficient production processes for clinical and commercial supply.
Research and development in next-generation TCR engineering, aiming to improve the efficacy and safety of TCR therapies.
Out-licensing agreements, offering access to its TCR technology for development in specific territories or for particular cancer targets.

Who is in the executive team of Alaunos Therapeutics?

Alaunos Therapeutics leadership team
  • Mr. Dale Curtis Hogue Jr.
    Mr. Dale Curtis Hogue Jr.
    Interim CEO & Director
  • Mr. Michael  Wong
    Mr. Michael Wong
    Vice President of Finance & Principal Accounting Officer